Comparative Pharmacology
Head-to-head clinical analysis: ADALAT versus ADALAT CC.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ADALAT versus ADALAT CC.
ADALAT vs ADALAT CC
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Dihydropyridine calcium channel blocker; inhibits calcium ion influx across cardiac and vascular smooth muscle cells, reducing peripheral vascular resistance and blood pressure.
Nifedipine, a dihydropyridine calcium channel blocker, inhibits calcium ion influx across cardiac and smooth muscle cell membranes, leading to vasodilation and decreased myocardial contractility.
10-20 mg orally three times daily; extended-release: 30-60 mg orally once daily; maximum 120 mg/day.
30 mg orally once daily; may titrate to 60 mg or 90 mg once daily based on response and tolerability.
None Documented
None Documented
Terminal elimination half-life: 2-5 hours (immediate-release); 8-14 hours (extended-release). Context: shorter half-life necessitates multiple daily dosing for immediate-release; extended-release allows once-daily dosing.
Terminal elimination half-life: 7-10 hours; clinical context: sustained-release formulation provides therapeutic concentrations over 24 hours with once-daily dosing, but half-life does not directly reflect drug effect duration due to slow absorption.
Renal: 70-80% as metabolites; Fecal: 15-20% as metabolites; <1% unchanged in urine
Renal: 70-80% as metabolites, fecal: 15-20% as metabolites, biliary: minimal (<5% unchanged).
Category C
Category C
Calcium Channel Blocker
Calcium Channel Blocker